US-based Contract Research Organization (CRO) Foundation Medicine Inc. has announced the expansion of its existing partnership with Chinese firm Sequanta Technologies Co., Ltd, to provide genomic profiling services in support of clinical research and development of oncology therapies in China.
Historical Collaboration and Future Plans
Since 2014, Foundation Medicine has utilized Sequanta as its in-house laboratory in China. The expanded partnership involves a tech transfer of Foundation’s in vitro diagnostic (IVD) genomic profiling tests. FoundationOne Liquid CDx, a blood-based comprehensive genomic profiling test, will initiate the transfer in November 2023, followed by FoundationOne CDx, a tissue-based test, in March 2024. These tests analyze over 300 cancer-related genes for genomic alterations, crucial for patient targeting in clinical trials and guiding treatment.
Sequanta’s Role and Global Standards
Sequanta acts as a partner laboratory to Foundation Medicine, conducting tests in China with unified parameters that include verification studies and concordance analysis. This ensures consistent performance and data quality across global sites, enabling the detection of study-specific biomarkers and supporting global regulatory submissions and companion diagnostic submissions in the US, Japan, and the EU.-Fineline Info & Tech
